Mesoblast Advances FDA Review for Rexlemestrocel-L in End-Stage Heart Failure

FDA Advances Rexlemestrocel-L Review for Critical Heart Failure Complication

Mesoblast Limited (ASX:MSB) has taken a significant regulatory step by receiving a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration (FDA) for rexlemestrocel-L. The company has also requested a modular review, a process designed to accelerate the assessment of this allogeneic cellular therapy aimed at preventing life-threatening gastrointestinal bleeding in end-stage heart failure patients implanted with left ventricular assist devices (LVADs).

Rexlemestrocel-L is positioned to address a dire unmet need: gastrointestinal bleeding caused by right ventricular dysfunction in patients reliant on LVADs. These devices, implanted in over 2,500 U.S. patients annually as destination therapy for advanced heart failure, carry a high risk of fatal bleeding complications linked to progressive right heart failure. Mesoblast’s therapy, leveraging immunoselected mesenchymal precursor cells, aims to modulate the severe inflammation that underpins these outcomes.

Orphan and RMAT Designations Highlight Regulatory Support

The FDA has granted rexlemestrocel-L both Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations for this indication, enabling rolling submissions and priority review pathways. These regulatory incentives reflect the therapy’s potential to address a rare condition with high mortality and irreversible morbidity. Mesoblast’s timing aligns with recent FDA guidance promoting flexibility in demonstrating substantial evidence of effectiveness for therapies targeting orphan diseases, as well as accommodating manufacturing and control flexibilities for cellular and gene therapies.

Chief Executive Dr Silviu Itescu emphasised the company’s commitment to collaborating closely with the FDA to bring rexlemestrocel-L to patients facing critical risks due to right heart failure complications. This filing follows extensive clinical investigation, including two large placebo-controlled trials involving 565 patients with NYHA class II/III heart failure and 159 end-stage patients with LVADs, underscoring the therapy’s clinical foundation.

Addressing a Growing Burden of Chronic Heart Failure

Chronic heart failure affects an estimated 26 million people worldwide, with the U.S. accounting for around 6.5 million cases. The condition’s progression through NYHA classes is marked by escalating inflammation and a grim prognosis, with mortality approaching 50% within five years beyond early class II disease. Despite advances in heart failure treatments, patients with significant inflammation remain vulnerable to major cardiac events.

LVAD implantation has become a critical intervention for end-stage heart failure, particularly in ischemic cases where functional recovery is limited. Mesoblast’s rexlemestrocel-L targets the inflammatory milieu believed to impede myocardial recovery and contribute to adverse outcomes in this population, representing a novel approach beyond conventional therapies.

Mesoblast’s Position in Cellular Medicine and Intellectual Property

Mesoblast is a recognised leader in allogeneic cellular medicines, with a broad intellectual property portfolio exceeding 1,000 patents and applications, providing protection through at least 2044. The company’s manufacturing capabilities enable industrial-scale production of off-the-shelf cell therapies, positioning it to meet global demand efficiently.

Alongside rexlemestrocel-L, Mesoblast’s FDA-approved Ryoncil® (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease has demonstrated commercial traction, supporting the company’s financial and developmental momentum. Recent financial manoeuvres, including a US$50 million credit facility, have fortified Mesoblast’s balance sheet ahead of anticipated commercial expansion.